Table 3.

Comparison of GMCs and seroconversion rates at 24 months after a single dose HPV vaccination between DoRIS and historical cohorts (per-protocol population^*)

	GMC ratio (DoRIS/historical cohort)	Adjusted GMC ratio†	Difference in seroconversion (DoRIS − historical control)
HPV16 IgG antibody
DoRIS vs CVT	1·30 (1·00 to 1·68)	..‡	0·4% (−3·1 to 5·1)
DoRIS vs IARC India	2·05 (1·61 to 2·61)	1·29 (0·91 to 1·82)	6·9% (2·4 to 13·1)
Aged <15 years (post hoc)	1·42 (1·10 to 1·83)	1·29 (0·94 to 1·76)	−0·7% (−4·0 to 5·0)
HPV18 IgG antibody
DoRIS vs CVT	1·23 (0·95 to 1·60)	..‡	−0·4% (−4·4 to 4·4)
DoRIS vs IARC India	2·57 (2·02 to 3·27)	1·75 (1·22 to 2·50)	21·0% (13·5 to 29·5)
Aged <15 years (post hoc)	2·12 (1·59 to 2·83)	1·75 (1·23 to 2·49)	15·2% (6·1 to 26·3)

Data in parentheses are 95% CIs. CVT=Costa Rica Vaccine trial. DoRIS=Dose Reduction Immunobridging and Safety Study. HPV=human papillomavirus. IARC=Institutional Agency for Research on Cancer. GMC=geometric mean concentration.

^*Includes DoRIS and CVT participants who were ELISA antibody negative and HPV DNA negative, and IARC India participants who were ELISA antibody negative, at baseline (before vaccination) for the HPV genotype under analysis.

^†Adjusted for age.

^‡Adjustment not done for comparisons between DoRIS and CVT because there is no overlap in the age range.